Titan Biotech Bonus Shares – Titan Biotech is likely to remain on investors’ radar next week after announcing a bonus share issue for eligible shareholders. The company has approved the issuance of one bonus share for every four shares held, with October 23, 2026, set as the record date. The announcement comes just months after the company carried out a stock split. According to the details shared in its filing, the bonus shares will have a face value of ₹2 each. The record date will determine which shareholders qualify for the additional shares, subject to the applicable eligibility and settlement rules.
October 23 Announced as the Bonus Share Record Date
Titan Biotech has fixed Friday, October 23, 2026, as the record date for its bonus issue. Companies use a record date to identify shareholders eligible to receive corporate benefits, including bonus shares.
Under the approved 1:4 ratio, an eligible investor holding four shares will receive one additional share without making a separate payment for that share. For example, a shareholder with 40 eligible shares would receive 10 bonus shares, taking the total holding to 50 shares after allotment.
Investors should also account for applicable market settlement timelines when determining eligibility. Buying shares close to the record date does not automatically guarantee entitlement, so shareholders should verify the relevant trading and settlement requirements before making an investment decision.
Bonus Share Allotment Scheduled for October 26
The company has scheduled October 26, 2026, for the allotment of bonus shares. According to the reported BSE filing details, Titan Biotech plans to issue 1,03,29,625 fully paid-up bonus equity shares.
The newly allotted shares are expected to become available for trading from October 27, 2026, the next working day after the stated allotment date.
The allotment and trading dates are important for shareholders who want to understand when the additional shares may appear in their demat accounts and when they can potentially be traded. Investors should refer to the company’s official exchange filings for any subsequent updates to the schedule.
What the Bonus Ratio Means for Shareholders
A bonus issue increases the number of shares held by an eligible investor without requiring an additional payment for the bonus shares. In Titan Biotech’s case, the approved ratio means one extra share for every four existing shares held on the relevant record date.
However, receiving additional shares does not automatically increase the overall market value of an investment by the same proportion. Following a bonus issue, the share price generally adjusts to reflect the larger number of shares, while the company’s underlying business value does not increase simply because more shares have been issued.
Investors therefore need to consider the company’s financial performance, valuation, business prospects and risk factors rather than treating a bonus announcement alone as a reason to buy or sell.
Titan Biotech Share Price and Recent Returns
Titan Biotech shares closed at ₹406.90 on Friday on the BSE, gaining 1.57% during the session, according to the figures provided. The company’s reported market capitalisation stood at approximately ₹1,681.25 crore.
The stock has also recorded substantial gains over the periods cited in the report. Its return for 2026 so far was reported at 91.44%, while the one-year return stood at 57.72%. Over two years, the stock gained 147%, and the three-year return was approximately 453.30%.
The company’s reported return on equity (ROE) is 22.35%. These historical figures describe past performance and do not indicate what the share price will do in the future. Market prices can fluctuate, and returns depend on the price at which an investor buys and sells.
With the record date approaching, shareholders may wish to review Titan Biotech’s official announcements for confirmation of the bonus issue timetable and eligibility conditions. The company’s recent share performance and corporate actions are relevant information, but neither guarantees future gains.